KY216

KY216 (compound C3) displays remarkable antiproliferative activities with IC₅₀ values of 6.3 nM, 9.2 nM, 8.3 nM, and 8.7 nM for K562, MCF-7, HT29, and HCT116 cells, respectively. Additionally, KY216 shows marked activity against Paclitaxel-resistant MCF-7 cells and A549 cells^[1].
KY216 (compound C3; 5-20 nM) downregulates the expression of acetyl-α-tubulin (Ac-α-tubulin) and upregulated the expression of detyrosinated-α-tubulin (DeY-α-tubulin) in a concentration-dependent manner^[1].
KY216 (compound C3; 5-20 nM; 24 hours) could arrest cancer cells in the G2/M phase, and induces MCF-7 cells apoptosis in a concentration-dependent manner^[1].
KY216 (compound C3; 5-20 nM; 24 hours) reduces Ser216 phosphorylation, resulting in cdc2 Tyr15 dephosphorylation and Thr161 phosphorylation, which ultimately leads to the activation of subsequent cdc2/cyclin B1 complex^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.